Set to be operational by the first quarter of 2022, the 140,000-ft2 facility will feature up to six 2000-L, single-use bioreactor systems along with additional harvest and purification equipment to produce up to 100 commercial batches annually.
KBI Biopharma, a JSR Life Sciences company, announced on Dec. 1, 2020 that it has opened a new $150 million commercial manufacturing facility in Research Triangle Park, NC.
Set to be operational by the first quarter of 2022, the 140,000-ft2 facility will feature up to six 2000-L, single-use bioreactor systems along with additional harvest and purification equipment to produce up to 100 commercial batches annually, a company press release said. The new site will also be equipped to provide accommodations for mammalian-based biologics manufacturing processes for KBI’s future and existing collaborators.
“Expansion of our US-based cell culture operations is a key investment to support our client’s commercialization strategies,” said KBI president and CEO Dirk Lange in the press release. “This state-of-the-art facility will leverage the latest innovation in automation and digitalization to best meet the needs for our clients.”
Source: KBI
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.